Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,762 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Postpartum Hemorrhage, Postpartum Preeclampsia, Postpartum Sepsis, Postpartum Depression, Patient Empowerment, Patient Education, Postpartum Care
Interventions: Video Education; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder, Treatment Resistant Depression
Interventions: Medtronic Percept PC DBS system; Device
Lead sponsor: Helen Mayberg, MD; Other
Eligibility: 25 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: End Stage Renal Disease, Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder, Compliance, Patient, Compliance, Medication, Mood, Pain, Energy Supply; Deficiency, Quality of Life, Blood Pressure, Heart Rate Fast
Interventions: Music therapy; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: New Orleans, Louisiana • Terrytown, Louisiana

Conditions: Major Depressive Disorder
Interventions: Placebo, Ketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more

Conditions: Depression
Interventions: Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression
Interventions: Scopolamine and naltrexone, placebo arm; Drug
Lead sponsor: The Taub Group; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder, Bipolar Disorder
Interventions: Cognitive Testing, MRI, PET; Behavioral · Other · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions: AXS-05 (dextromethorphan and bupropion) oral tablets; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 51
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more

Conditions: Major Depressive Disorder
Interventions: Zelquistinel; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Montclair, California + 27 more

Conditions: Major Depressive Disorder, Anxiety
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Tuscon, Arizona • Garden Grove, California • Oceanside, California + 18 more

Conditions: Major Depressive Episode
Interventions: Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy; Procedure
Lead sponsor: The George Institute; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Augusta, Georgia • Charleston, South Carolina

Conditions: Major Depressive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Sharmin Ghaznavi; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Depression
Interventions: Cognitive behavioral therapy (CBT) for insomnia, Clinician monitoring; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 25 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Postpartum Major Depression
Interventions: repeated mood measures and phone depression care management; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Borderline Personality Disorder
Interventions: Escitalopram; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder
Interventions: Interactive voice messaging or Interactive voice messaging + psycho ed materials; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 75 Years
Enrollment: 6,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depression
Interventions: Herbal extract, Sertraline, Lactose monohydrate; Dietary Supplement · Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depression
Interventions: Sertraline, Hypericum perforatum (St. John's wort); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 12
States / cities: San Diego, California • Stanford, California • Torrance, California + 9 more

Conditions: Depression - Major Depressive Disorder
Interventions: Mediterranean Diet, Time-Restricted Eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Depression
Interventions: Novasoy; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 34 more

Conditions: Bipolar Depression
Interventions: Lumateperone, Placebo; Drug · Other
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Sherman Oaks, California • Miami, Florida + 11 more

Conditions: Major Depressive Disorder
Interventions: ANC-501; Drug
Lead sponsor: Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Orange, California • Largo, Florida • Lauderhill, Florida + 5 more

Search by objective public record fields.

Postpartum Video Education

DBS for TRD With the Medtronic Percept PC

Music Therapy and Dialysis: A Pilot Investigation Into the Effectiveness of Patient-Selected Music Interventions on Physiological, Psychological, and Quality-of-Life Outcomes

A Study of Ketamine in Patients With Treatment-resistant Depression

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

MRI-Guided High-Definition Transcranial Direct Current Stimulation (tDCS) for Depression

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Examination of Glutamate and mGluR5 in Psychiatric Disorders

Open-Label Safety Study of AXS-05 in Subjects With Depression

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

The RAFT ECT Study

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Cognitive Behavioral Therapy for the Treatment of Depression-Related Insomnia

T- BOOM Teens--Building Options and Opportunities for Moms

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Antidepressant Adherence Via AD_IVR

Rhodiola Rosea Therapy of Major Depressive Disorder

Treatment of Major Depression With St. John's Wort (Hypericum)

Nutritional Intervention for College Students With Depression

Examination of a Soy-Based Supplement for Major Depression

Study of Rapastinel as Monotherapy in Patients With MDD

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

ANC-501 in the Treatment of Adults With Major Depressive Disorder